Research
Hormonal
Plasma IL-15 protein levels increase acutely after resistance exercise but do not change chronically with training and are not associated with variability in muscle responses.
Measuring blood IL-15 levels is not a useful predictor of who will gain muscle from resistance training. Focus on consistent training and nutrition rather than trying to manipulate circulating IL-15 levels.
GoodRefutesHIGH confidence
Plasma IL-15 protein was significantly increased (P < 0.05) immediately after acute resistance exercise but did not change with training and was not associated with variability in muscle responses with training.
Why this rating
Controlled measurement of plasma levels before and after training.
Source
Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses
Steven E. Riechman et al. · Journal of Applied Physiology · 2004
DOI 10.1152/japplphysiol.00491.2004
cohort · n=153Cited 230×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Genetic variation in the IL15RA gene (specifically the PstI polymorphism in exon 7) is strongly associated with greater muscle hypertrophy (lean mass gain) in response to resistance exercise training, although it is associated with reduced muscle quality gains.Good
- While IL15RA genetic variation (PstI polymorphism) is associated with greater muscle hypertrophy, it is also associated with reduced muscle quality (strength relative to muscle size) gains.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →